AnteoTech Ltd (ASX: ADO) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
AnteoTech Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$55.39 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.41 billion
Earnings per share
-0.006
Dividend per share
N/A
Year To Date Return
-36.11%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
AnteoTech Ltd (ASX: ADO)
Latest News
Healthcare Shares
Ellume is making news and these ASX shares are surging, again
Healthcare Shares
AnteoTech (ASX:ADO) share price lifts as Ellume US sales ramp-up
⏸️ ASX Shares
The 5 best ASX shares of FY21 revealed
Healthcare Shares
The 5 best performing ASX healthcare shares of FY21, did yours make the cut?
Share Gainers
These 3 ASX biotech shares are all up at least 120% in a year
Share Fallers
Why AnteoTech, Fortescue, Synlait, & TPG shares are tumbling lower
Share Gainers
Why the AnteoTech (ASX:ADO) share price is racing higher
Capital Raising
Why the AnteoTech (ASX:ADO) share price is soaring 9% higher today
Share Gainers
Why AnteoTech, Aristocrat Leisure, BWX, & Xero shares are storming higher
Healthcare Shares
Why the Anteotech (ASX:ADO) share price is soaring 10% today
Share Fallers
Why AnteoTech, Domain, Flight Centre, & Nick Scali are sinking today
Capital Raising
The AnteoTech (ASX:ADO) share price is on watch. Here's why.
Frequently Asked Questions
-
No, AnteoTech does not pay dividends at this time.
-
AnteoTech Ltd listed on the ASX on 7 April 2000.
ADO ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About AnteoTech Ltd
AnteoTech Ltd (ASX: ADO) is a biotechnology company that uses its globally patented particle surface management technology to develop specialty products and services. The company's two key fields are end-user diagnostic products and battery technology.
Its Life Sciences division is centred around AnteoBind, a product that connects biological and synthetic surfaces. The technology has various applications and also assists other diagnostic researchers in developing new products and medical devices.
Meantime, the company's Energy division uses AnteoX binding technology to boost the performance of silicon-containing anodes delivering increased capacity, extended cycle life, and superior mechanical properties in lithium-ion batteries.
ADO Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 24 Apr 2024 | $0.02 | $0.00 | 0.00% | 99,301 | $0.02 | $0.02 | $0.02 |
| 23 Apr 2024 | $0.02 | $0.00 | 0.00% | 459,136 | $0.02 | $0.02 | $0.02 |
| 22 Apr 2024 | $0.02 | $0.00 | 0.00% | 1,479,909 | $0.02 | $0.02 | $0.02 |
| 19 Apr 2024 | $0.02 | $0.00 | 0.00% | 451,158 | $0.02 | $0.02 | $0.02 |
| 18 Apr 2024 | $0.02 | $0.00 | 0.00% | 5,556,805 | $0.02 | $0.02 | $0.02 |
| 17 Apr 2024 | $0.02 | $0.00 | 0.00% | 3,087,731 | $0.02 | $0.02 | $0.02 |
| 16 Apr 2024 | $0.02 | $0.00 | 0.00% | 3,783,499 | $0.02 | $0.02 | $0.02 |
| 15 Apr 2024 | $0.02 | $0.00 | 0.00% | 6,756,642 | $0.02 | $0.02 | $0.02 |
| 12 Apr 2024 | $0.02 | $0.00 | 0.00% | 4,318,670 | $0.02 | $0.02 | $0.02 |
| 11 Apr 2024 | $0.02 | $0.00 | 0.00% | 10,627,628 | $0.03 | $0.03 | $0.02 |
| 10 Apr 2024 | $0.03 | $0.00 | 0.00% | 608,414 | $0.03 | $0.03 | $0.03 |
| 09 Apr 2024 | $0.03 | $0.00 | 0.00% | 3,562,193 | $0.03 | $0.03 | $0.03 |
| 08 Apr 2024 | $0.03 | $-0.01 | -28.57% | 17,696,798 | $0.03 | $0.03 | $0.03 |
| 03 Apr 2024 | $0.04 | $0.00 | 0.00% | 1,171,606 | $0.04 | $0.04 | $0.03 |
| 02 Apr 2024 | $0.04 | $0.00 | 0.00% | 667,210 | $0.04 | $0.04 | $0.04 |
| 28 Mar 2024 | $0.04 | $0.00 | 0.00% | 781,617 | $0.04 | $0.04 | $0.04 |
| 27 Mar 2024 | $0.04 | $0.00 | 0.00% | 2,814,836 | $0.04 | $0.04 | $0.04 |
| 26 Mar 2024 | $0.04 | $0.00 | 0.00% | 190,257 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 22 Dec 2023 | Geoffrey Cumming | Expiry | 1,500,000 | $51,000 |
Options expired.
|
| 14 Nov 2023 | Glenda McLoughlin | Issued | 468,750 | $12,656 |
Participation in share purchase plan.
|
| 14 Nov 2023 | Glenda McLoughlin | Issued | 1,500,000 | $21,900 |
Issue of options.
|
| 14 Nov 2023 | Katherine Woodthorpe | Issued | 1,500,000 | $21,900 |
Issue of options.
|
| 14 Nov 2023 | Geoffrey Cumming | Issued | 468,750 | $12,656 |
Participation in share purchase plan.
|
| 14 Nov 2023 | Geoffrey Cumming | Issued | 1,500,000 | $21,900 |
Issue of options.
|
| 14 Nov 2023 | David Radford | Issued | 10,000,000 | $146,000 |
Issue of options.
|
| 14 Nov 2023 | David Radford | Issued | 468,750 | $12,656 |
Participation in share purchase plan.
|
| 14 Nov 2023 | Ewen Crouch | Issued | 2,500,000 | $36,500 |
Issue of options.
|
| 14 Nov 2023 | Ewen Crouch | Issued | 468,750 | $12,656 |
Participation in share purchase plan.
|
| 11 Sep 2023 | Ewen Crouch | Buy | 937,500 | $30,000 |
Participation in share purchase plan.
|
| 11 Sep 2023 | Geoffrey Cumming | Buy | 937,500 | $30,000 |
Participation in share purchase plan.
|
| 11 Sep 2023 | David Radford | Buy | 937,500 | $30,000 |
Participation in share purchase plan.
|
| 11 Sep 2023 | Glenda McLoughlin | Buy | 937,500 | $30,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Katherine Leslie Woodthorpe | Non-Executive Director | Sep 2021 |
Dr Woodthorpe AO is an experienced Chair and Non-Executive Director serving for over 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has sat on the boards of a number of healthcare companies including Ventracor and Sirtex Ltd. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. He is also a Member of the Audit and Risk Committee and Member of the Energy Advisory Board.
|
| Dr Geoffrey James Cumming | Non-Executive Director | Apr 2009 |
Dr Cumming has over 20 years' experience in the healthcare and biotechnology market. He was also Managing Director and CEO of Biosceptre Ltd. During his tenure he was responsible for taking research from Sydney University through to product registration. This involved capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. He is also a member of Risk Committee and Member of Clinical Advisory Board.
|
| Ms Glenda McLoughlin | Non-Executive Director | Sep 2021 |
Ms McLoughlin is an experienced Chair and Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. He is also a Member of the Remuneration and Nomination Committee, Chair of the Audit and Risk Committee and Chair of the Energy Advisory Board.
|
| Mr Richard Shubrick Martin | Non-Executive Director | Sep 2005 |
Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.
|
| Mr David John Radford | Chief Executive OfficerManaging Director | Oct 2022 |
Mr Radford is an internationally experienced CEO and Company Director with a track record of identifying and delivering profitable growth across a range of industries and geographies. He has direct experience in coordinating international teams, executing business turnarounds, product development and product launches, and operational initiatives to drive material growth in revenue and profits. He is a member of Risk Committee.
|
| Mr Ewen Graham Wolseley Crouch | Non-Executive ChairmanNon-Executive Director | Apr 2022 |
Mr Crouch was a Partner at Allens from 1998 to 2013 where his roles included Chairman of Partners, Co-Head Mergers and Acquisitions and Equity Capital Markets, Executive Partner - Asian Offices and Deputy Managing Partner, as well as 11 years' service on its board. He served as a director of Mission Australia between 1995 and 2016, including 7 years as its Chairman. He is a Member of the Audit and Risk Committee.
|
| Mr Andrew Cook | Company Secretary | Aug 2023 |
-
|
| Andrew Cook | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Levenson Investments Pty Ltd | 95,932,718 | 4.41% |
| Marcolongo Nominees Pty Ltd | 55,634,380 | 2.56% |
| First Cape Management Pty Ltd | 55,195,509 | 2.54% |
| Addison Lake Quality Hire Pty Limited | 38,844,879 | 1.79% |
| Fossil Super Pty Ltd | 34,100,000 | 1.57% |
| Bond Street Custodians Limited | 24,130,249 | 1.11% |
| Palm Beach Nominees Pty Limited | 23,437,500 | 1.08% |
| BNP Paribas Nominees Pty Ltd | 23,114,127 | 1.06% |
| Mr Peter Frederick Kemmis | 22,385,655 | 1.03% |
| Computer Visions Pty Ltd | 22,132,994 | 1.02% |
| Marcolongo Nominees Pty Ltd (ii) | 21,897,938 | 1.01% |
| Mcrae Superannuation Pty Ltd | 20,125,000 | 0.93% |
| Mrs Mary Curtis | 19,617,450 | 0.90% |
| Mr Anthony William Olding & Mrs Caroline Anne Olding | 18,817,142 | 0.87% |
| Bnp Paribas Noms Pty Ltd | 18,175,529 | 0.84% |
| AWO & CAO Investments Pty Ltd | 17,497,856 | 0.80% |
| Terry & Linden Deavin Super Pty Ltd | 16,100,000 | 0.74% |
| HSBC Custody Nominees (Australia) Limited | 15,667,163 | 0.72% |
| Mrs Elaine Janice Salisbury | 15,400,000 | 0.71% |
| Mr Richard Shubrick Martin & Mrs Fiona Diana Martin | 14,862,514 | 0.68% |
